ANNUAL REPORT

2017-18

30 years of Responsible Entrepreneurship

"You are what your deep driving desire is. As your desire is, so is your will. As your will is, so is your deed. As your deed is, so is your destiny."

Brihadaranyaka Upanishad IV.4.5

NOTES

  1. FY1988 Revenue and PAT numbers were for the year ending June 30, 1988. FY2018 numbers are reported as per Ind AS, rest of the numbers are as reported.
  2. Normalised profit excludes exceptional items. FY2018 Normalised Net Profit excludes synergies on account of merger of subsidiaries in Financial Services segment.
  3. Annualised shareholder returns computed using Bloomberg as on April 30, 2018 (assumed dividend reinvested in the stock).
  4. For the period FY2012 to FY2018.
  5. For the period FY2013 to FY2018.

SINCE 1988:

23%

C A G R

ANNUAL REVENUES OVER THE LAST 30 YEARS 1

29%

C A G R

NET PROFIT OVER THE LAST 30 YEARS 1,2

29%

A N N U A L I S E D R E T U R N

TO SHAREHOLDERS OVER THE LAST 30 YEARS 3

SINCE ABBOTT DEAL:

29%

C A G R

REVENUE OVER THE LAST 6 YEARS 4

55%

C A G R

NORMALISED NET PROFIT OVER THE LAST 6 YEARS 2,4

40%

A N N U A L I S E D R E T U R N

TO SHAREHOLDERS OVER THE LAST
5 YEARS 3,5

Piramal Enterprises
at a Glance

Piramal Enterprises Limited (PEL) is one of India’s large diversified companies, with a presence in Financial Services, Pharmaceuticals and Healthcare Insight & Analytics. PEL’s consolidated revenues were over $1.6 billion in FY2018, with around 46% of revenues generated from outside India.

know more

Highlights of
the company

6,843

Employees

30

Offices across the globe

29%

Fy2018 DIVIDEND Payout Ratio

`44,002Cr

Market Capitalisation as on March 31, 2018

29%

Annualised shareholder return over 30 years

OVER A

BILLION

DOllar raise in fy2018

Our Business at a Glance

2/03

Pharma —
Business at a Glance

know more

3/03

Healthcare Insight & Analytics — Business at a Glance

know more

Chairman's Message

Dear Shareholders,

My warm greetings to all of you.

Our 30-year journey

The Company has consistently transformed itself over the last 30 years. In 1988, we entered the pharmaceuticals space and in over a period of two decades, we became one of the top pharma companies in India. Consequent to the sale of our Domestic Formulations business to Abbott in 2010, we have once again transformed our business model.

Ajay G. Piramal

Chairman

know more

23%

30-YEAR CAGR
OF REVENUE

29%

30-YEAR CAGR
OF NET PROFIT

`5,680 Cr

RETURNED TO ITS
SHAREHOLDERS IN THE
FORM OF DIVIDENDS, SPECIAL
DIVIDEND AND BUYBACK
SINCE FY2011

Key Performance Indicators

Consistently delivering strong performance across financial,
operational and sustainability parameters.

TOTAL REVENUE1 (IN ` CR)
 

  • FY2013 3,544
  • FY20144,503
  • FY20155,123
  • FY20166,381
  • FY20178,547
  • FY201810,639

NORMALISED NET PROFIT * (IN ` CR) AND NET PROFIT MARGIN (%)

  • FY2013-6%-227
  • FY2014-11%-501
  • FY20158%   421
  • FY201614%   905
  • FY201715% 1,252
  • FY201815% 1,551

MARKET CAP(IN ` CR)
 

  • FY2013 10,549
  • FY20149,465
  • FY201515,029
  • FY201617,885
  • FY201732,825
  • FY201844,002

30-year Journey of Piramal Enterprises

Prior to 1988, the Group was involved in Textile and other businesses. Since the acquisition of Nicholas Laboratories in 1988, the Company reinvented itself multiple times, constantly evolved and grew, with a clear objective of consistently creating significant value for all its stakeholders.

know more

PHASE 1: FY1988 AND EARLIER

Exited Textile business and entered Pharma

PHASE 2: FY 1989- FY 2011

Created one of the leading Indian Pharma companies

PHASE 3: FY 2012 – FY 2018

Built a strong Financial Services business and scaled up the balance Pharma business

PHASE 4: LOOKING INTO THE FUTURE

Future strategy